Recent advances in development and delivery of non-viral nucleic acid therapeutics for brain tumor therapy.

in Pharmacology & therapeutics by Donat Kögel, Achim Temme, Achim Aigner

TLDR

  • The study reviews recent advancements in nucleic acid-based therapy for HGG and highlights its potential for improved treatment options.
  • The study provides a comprehensive overview of preclinical and clinical developments, emphasizing the importance of continued research in this area.

Abstract

High grade gliomas (HGG) are a group of CNS tumors refractory to currently existing therapies, which routinely leads to early recurrence and a dismal prognosis. Recent advancements in nucleic acid-based therapy using a wide variety of different molecular targets and non-viral nanocarrier systems suggest that this approach holds significant potential to meet the urgent demand for improved therapeutic options for the treatment of these tumors. This review provides a comprehensive and up-to-date overview on the current landscape and progress of preclinical and clinical developments in this rapidly evolving and exciting field of research, including optimized nanocarrier delivery systems, promising therapeutic targets and tailor-made therapeutic strategies for individualized HGG patient treatment.

Overview

  • The study focuses on high-grade gliomas (HGG) and the lack of effective therapies, highlighting the need for improved treatment options.
  • The study reviews recent advancements in nucleic acid-based therapy, including various molecular targets and non-viral nanocarrier systems.
  • The study aims to provide a comprehensive overview of the current landscape and progress in preclinical and clinical developments in this area.

Comparative Analysis & Findings

  • The review discusses various nanocarrier delivery systems and their potential for optimized delivery of nucleic acid-based therapies.
  • The study highlights various therapeutic targets and personalized treatment strategies for individualized HGG patient treatment.
  • The review presents a comprehensive overview of preclinical and clinical developments, providing insights into the current state of research in this field.

Implications and Future Directions

  • The study's findings suggest a promising future for nucleic acid-based therapy in the treatment of HGG, with significant potential for improved outcomes.
  • Future research directions may focus on refining nanocarrier delivery systems and therapeutic targets to better meet the unique needs of HGG patients.
  • The study's comprehensive overview provides a foundation for future research, highlighting the importance of continued investigation into this area.
Read Full Article